Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study

Hdl Handle:
http://hdl.handle.net/10147/315469
Title:
Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study
Authors:
McGorrian, Catherine M; Lyster, Sarah; Roy, Andrew; Tarrant, Heloise; Codd, Mary; Doran, Peter; Fitzgibbon, Maria; Galvin, Joseph; Mahon, Niall G
Citation:
BMC cardiovascular disorders. 2013 Sep 11;13(1):70
Journal:
BMC cardiovascular disorders. 2013 Sep 11;13(1):70
Issue Date:
11-Sep-2013
URI:
http://dx.doi.org/10.1186/1471-2261-13-70; http://hdl.handle.net/10147/315469
Abstract:
Abstract Background Hypertrophic cardiomyopathy (HCM) is a genetic condition, and relatives of affected persons may be at risk. Cardiac troponin biomarkers have previously been shown to be elevated in HCM. This study examines the new highly-sensitive cardiac troponin I (hsTnI) assay in a HCM screening population. Methods Nested case–control study of consecutive HCM sufferers and their relatives recruited from May 2010 to September 2011. After informed consent, participants provided venous blood samples and clinical and echocardiographic features were recorded. Associations between the natural log (ln) of the contemporary troponin I (cTnI) and hsTnI assays and markers of cardiac hypertrophy were examined. Multiple regression models were fitted to examine the predictive ability of hsTnI for borderline or definite HCM. Results Of 107 patients, 24 had borderline and 19 had definite changes of HCM. Both TnI assays showed significant, positive correlations with measures of cardiac muscle mass. After age and sex adjustment, the area under the receiver operator characteristic (AUROC) curve for the outcome of HCM was 0.78, 95% CI [0.65, 0.90], for ln(hsTnI), and 0.66, 95% CI [0.51, 0.82], for ln(cTnI) (p=0.11). Including the hsTnI assay in a multiple-adjusted “screening” model for HCM resulted in a non-significant improvement in both the AUROC and integrated discrimination index. Conclusions Both cTnI and hsTnI show a graded, positive association with measures of cardiac muscle mass in persons at risk of HCM. Further studies will be required to evaluate the utility of these assays in ECG- and symptom-based identification of HCM in at-risk families.
Item Type:
Article
Language:
en
Keywords:
SCREENING
Local subject classification:
HEART DISEASE

Full metadata record

DC FieldValue Language
dc.contributor.authorMcGorrian, Catherine Men_GB
dc.contributor.authorLyster, Sarahen_GB
dc.contributor.authorRoy, Andrewen_GB
dc.contributor.authorTarrant, Heloiseen_GB
dc.contributor.authorCodd, Maryen_GB
dc.contributor.authorDoran, Peteren_GB
dc.contributor.authorFitzgibbon, Mariaen_GB
dc.contributor.authorGalvin, Josephen_GB
dc.contributor.authorMahon, Niall Gen_GB
dc.date.accessioned2014-04-07T11:00:12Z-
dc.date.available2014-04-07T11:00:12Z-
dc.date.issued2013-09-11-
dc.identifier.citationBMC cardiovascular disorders. 2013 Sep 11;13(1):70en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2261-13-70-
dc.identifier.urihttp://hdl.handle.net/10147/315469-
dc.description.abstractAbstract Background Hypertrophic cardiomyopathy (HCM) is a genetic condition, and relatives of affected persons may be at risk. Cardiac troponin biomarkers have previously been shown to be elevated in HCM. This study examines the new highly-sensitive cardiac troponin I (hsTnI) assay in a HCM screening population. Methods Nested case–control study of consecutive HCM sufferers and their relatives recruited from May 2010 to September 2011. After informed consent, participants provided venous blood samples and clinical and echocardiographic features were recorded. Associations between the natural log (ln) of the contemporary troponin I (cTnI) and hsTnI assays and markers of cardiac hypertrophy were examined. Multiple regression models were fitted to examine the predictive ability of hsTnI for borderline or definite HCM. Results Of 107 patients, 24 had borderline and 19 had definite changes of HCM. Both TnI assays showed significant, positive correlations with measures of cardiac muscle mass. After age and sex adjustment, the area under the receiver operator characteristic (AUROC) curve for the outcome of HCM was 0.78, 95% CI [0.65, 0.90], for ln(hsTnI), and 0.66, 95% CI [0.51, 0.82], for ln(cTnI) (p=0.11). Including the hsTnI assay in a multiple-adjusted “screening” model for HCM resulted in a non-significant improvement in both the AUROC and integrated discrimination index. Conclusions Both cTnI and hsTnI show a graded, positive association with measures of cardiac muscle mass in persons at risk of HCM. Further studies will be required to evaluate the utility of these assays in ECG- and symptom-based identification of HCM in at-risk families.-
dc.language.isoenen
dc.subjectSCREENINGen_GB
dc.subject.otherHEART DISEASEen_GB
dc.titleUse of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent studyen_GB
dc.typeArticleen
dc.identifier.journalBMC cardiovascular disorders. 2013 Sep 11;13(1):70en_GB
dc.language.rfc3066en-
dc.rights.holderCatherine M McGorrian et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2014-04-05T11:14:43Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.